Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 515

The DOI matches its Crossref record.

Metal-based anticancer chemotherapeutic agents

Muhammad, Nafees, Guo, Zijian·2014·Current Opinion in Chemical Biology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cbpa.2014.02.003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 53

  1. Rosenberg, 1965, Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode, Nature, 205, 698, 10.1038/205698a0 · DOI · Paper page
  2. Guo, 1999, Medicinal inorganic chemistry, Adv Inorg Chem, 49, 183, 10.1016/S0898-8838(08)60271-8 · DOI · Paper page
  3. Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat Rev Cancer, 7, 573, 10.1038/nrc2167 · DOI · Paper page
  4. Wang, 2013, Targeting and delivery of platinum-based anticancer drugs, Chem Soc Rev, 42, 202, 10.1039/C2CS35259A · DOI · Paper page
  5. Butler, 2013, Targeted delivery of platinum-based anticancer complexes, Curr Opin Chem Biol, 17, 175, 10.1016/j.cbpa.2013.01.004 · DOI · Paper page
  6. Barry, 2013, Exploration of the medical periodic table: towards new targets, Chem Commun (Camb), 49, 5106, 10.1039/c3cc41143e · DOI · Paper page
  7. Rosenberg, 1969, Platinum compounds: a new class of potent antitumour agents, Nature, 222, 385, 10.1038/222385a0 · DOI · Paper page
  8. Wheate, 2010, The status of platinum anticancer drugs in the clinic and in clinical trials, Dalton Trans, 39, 8113, 10.1039/c0dt00292e · DOI · Paper page
  9. Wexselblatt, 2012, What do we know about the reduction of Pt(IV) pro-drugs?, J Inorg Biochem, 117, 220, 10.1016/j.jinorgbio.2012.06.013 · DOI · Paper page
  10. Kozubik, 2005, High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro, Biochem Pharmacol, 69, 373, 10.1016/j.bcp.2004.09.005 · doi:10.1016/j.bcp.2004.09.005
  11. Wilson, 2011, Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes, Inorg Chem, 50, 3103, 10.1021/ic2000816 · DOI
  12. Medrano, 2013, Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs, Chem Commun (Camb), 49, 4806, 10.1039/c3cc38416k · doi:10.1039/c3cc38416k
  13. Varbanov, 2012, Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs, Dalton Trans, 41, 14404, 10.1039/C2DT31366A · doi:10.1039/c2dt31366a
  14. Ravera, 2012, Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin, Dalton Trans, 41, 3313, 10.1039/c2dt11874b · doi:10.1039/c2dt11874b
  15. Pichler, 2013, Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes, Inorg Chem, 52, 8151, 10.1021/ic400816g · doi:10.1021/ic400816g
  16. Farrer, 2010, A potent trans-diimine platinum anticancer complex photoactivated by visible light, Angew Chem Int Ed, 49, 8905, 10.1002/anie.201003399 · doi:10.1002/anie.201003399
  17. Song, 2013, Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations, Bioconjugate Chem, 24, 1733, 10.1021/bc400281a · DOI
  18. Aryal, 2010, Polymer cisplatin conjugate nanoparticles for acid-responsive drug delivery, ACS Nano, 4, 251, 10.1021/nn9014032 · DOI · Paper page
  19. Kolishetti, 2010, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy, PNAS, 107, 17939, 10.1073/pnas.1011368107 · DOI · Paper page
  20. Xiao, 2012, A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance, Biomaterials, 33, 6507, 10.1016/j.biomaterials.2012.05.049 · DOI · Paper page
  21. Graf, 2012, αVβ3 integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug, ACS Nano, 6, 4530, 10.1021/nn301148e · DOI · Paper page
  22. Wedlock, 2013, NanoSIMS multi-element imaging reveals internalisation and nucleolar targeting for a highly-charged polynuclear platinum compound, Chem Commun (Camb), 49, 6944, 10.1039/c3cc42098a · doi:10.1039/c3cc42098a
  23. Manzotti, 2000, BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin, Clin Cancer Res, 6, 2626
  24. Zhao, 2006, A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity, Dalton Trans, 2617, 10.1039/b601739h · doi:10.1039/b601739h
  25. Wang, 2011, Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin, Inorg Chem, 50, 12661, 10.1021/ic201712e · doi:10.1021/ic201712e
  26. Olivova, 2011, Unique DNA binding mode of antitumor trinuclear tridentate platinum(II) compound, Mol Pharm, 8, 2368, 10.1021/mp200298g · DOI
  27. Zerzankova, 2010, Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers, Biochem Pharmacol, 80, 344, 10.1016/j.bcp.2010.04.013 · doi:10.1016/j.bcp.2010.04.013
  28. Lin, 2011, Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes, Apoptosis, 16, 288, 10.1007/s10495-010-0562-0 · DOI
  29. Komeda, 2011, A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high in vivo antitumor activity against pancreatic cancer, ChemMedChem, 6, 987, 10.1002/cmdc.201100141 · doi:10.1002/cmdc.201100141
  30. Komeda, 2013, Synthesis of antitumor azolato-bridged dinuclear platinum(II) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles, Metallomics, 5, 461, 10.1039/c3mt00040k · doi:10.1039/c3mt00040k
  31. Brown, 2012, Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity, Dalton Trans, 41, 11330, 10.1039/c2dt31313h · doi:10.1039/c2dt31313h
  32. Sava, 2011, Metal-based antitumour drugs in the post-genomic era: what comes next?, Dalton Trans, 40, 9069, 10.1039/c1dt10522a · DOI · Paper page
  33. Lakomska, 2013, Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands, Dalton Trans, 42, 6219, 10.1039/c2dt32216a · doi:10.1039/c2dt32216a
  34. Pierroz, 2012, Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid, J Am Chem Soc, 134, 20376, 10.1021/ja307288s · DOI · Paper page
  35. Li, 2012, Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers, Dalton Trans, 41, 1138, 10.1039/C1DT11950H · doi:10.1039/c1dt11950h
  36. Qian, 2013, The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes, Metallomics, 5, 844, 10.1039/c3mt20270d · DOI
  37. Ang, 2011, Organometallic ruthenium-based antitumor compounds with novel modes of action, J Organomet Chem, 696, 989, 10.1016/j.jorganchem.2010.11.009 · DOI · Paper page
  38. Suss-Fink, 2010, Arene ruthenium complexes as anticancer agents, Dalton Trans, 39, 1673, 10.1039/B916860P · DOI
  39. Kilpin, 2013, Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands, Dalton Trans, 42, 2008, 10.1039/C2DT32333H · doi:10.1039/c2dt32333h
  40. Khan, 2013, Arene ruthenium dichloro complexes containing isonicotinic ester ligands: synthesis, molecular structure and cytotoxicity, J Organomet Chem, 730, 49, 10.1016/j.jorganchem.2012.10.016 · doi:10.1016/j.jorganchem.2012.10.016
  41. Romero-Canelon, 2013, The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway, J Med Chem, 56, 1291, 10.1021/jm3017442 · DOI · Paper page
  42. Barry, 2012, Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies, Chem Soc Rev, 41, 3264, 10.1039/c2cs15300a · DOI
  43. Ott, 2009, On the medicinal chemistry of gold complexes as anticancer drugs, Coord Chem Rev, 253, 1670, 10.1016/j.ccr.2009.02.019 · DOI · Paper page
  44. Bindoli, 2009, Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs, Coord Chem Rev, 253, 1692, 10.1016/j.ccr.2009.02.026 · DOI · Paper page
  45. Serratrice, 2012, Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1, Dalton Trans, 41, 3287, 10.1039/c2dt11913g · doi:10.1039/c2dt11913g
  46. Zou, 2013, Gold(III) complexes containing N-heterocyclic carbene ligands: thiol “switch-on” fluorescent probes and anti-cancer agents, Angew Chem Int Ed, 52, 2930, 10.1002/anie.201209787 · DOI · Paper page
  47. Ronconi, 2009, The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes, Dalton Trans, 10670, 10.1039/b913597a · doi:10.1039/b913597a
  48. Zhang, 2013, Deubiquitinases as potential anti-cancer targets for gold(iii) complexes, Chem Commun (Camb), 49, 5153, 10.1039/c3cc41766b · DOI
  49. Buettner, 2012, Bioinorganic chemistry of titanium, Chem Rev, 112, 1863, 10.1021/cr1002886 · DOI · Paper page
  50. Tshuva, 2009, Modern cytotoxic titanium(IV) complexes; insights on the enigmatic involvement of hydrolysis, Coord Chem Rev, 253, 2098, 10.1016/j.ccr.2008.11.015 · DOI
  51. Glasner, 2011, A marked synergistic effect in antitumor activity of salan titanium(IV) complexes bearing two differently substituted aromatic rings, J Am Chem Soc, 133, 16812, 10.1021/ja208219f · DOI
  52. Meker, 2012, High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species, Angew Chem Int Ed Engl, 51, 10515, 10.1002/anie.201205973 · doi:10.1002/anie.201205973
  53. Tzubery, 2011, Trans titanium(IV) complexes of salen ligands exhibit high antitumor activity, Inorg Chem, 50, 7946, 10.1021/ic201296h · DOI

Cited by

See all 515

Metadata

Authors
Muhammad, N., & Guo, Z.
Venue
Current Opinion in Chemical Biology
Publisher
Elsevier BV
Published
2014-04
Volume
19
Pages
144-153
ISSN
1367-5931 (ISSN-L)
OpenAlex
W2090858808
Cited by
515
References
0
FWCI
5.94
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Basic Research Program of China (2011CB935800)
  • National Natural Science Foundation of China (21271100, 91213305, 10979019, 21131003, 21021062)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metal-based anticancer chemotherapeutic agents. https://app.cochat.ai/papers/10.1016/j.cbpa.2014.02.003
The paper
Muhammad, N., & Guo, Z. (2014). Metal-based anticancer chemotherapeutic agents. Current Opinion in Chemical Biology. https://doi.org/10.1016/j.cbpa.2014.02.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.